Liver Cancer is a premier, peer-reviewed journal dedicated to the comprehensive study and advancement of knowledge surrounding liver neoplasms. Published by KARGER and headquartered in Switzerland, this journal has been an open-access platform since 2012, providing researchers with invaluable insights into the rapidly evolving field of hepatology and oncology. With an impressive impact factor that places it in the Q1 category for both Hepatology and Oncology in 2023, Liver Cancer stands out as a high-impact conduit for groundbreaking research, ranking #19 out of 404 in Medicine _ Oncology and #6 out of 82 in Medicine _ Hepatology according to Scopus. Researchers, practitioners, and students are encouraged to engage with the journal's content, which encompasses clinical studies, basic research, and reviews that contribute significantly to understanding liver cancer dynamics, diagnosis, and treatment strategies. This journal not only facilitates the dissemination of knowledge but also fosters collaboration in a well-established and impactful global scientific community.

JOURNAL OF HEPATOLOGY, published by Elsevier, stands as a preeminent source in the field of Hepatology, with its impact underscored by a remarkable 2023 Category Quartile of Q1 and a Scopus rank of 3rd out of 82 journals, placing it in the 96th percentile for the discipline. Since its inception in 1985, this journal has been a vital conduit for the dissemination of pioneering research, clinical studies, and reviews related to liver diseases and their impact on global health. Although it currently does not offer open access options, the journal is committed to providing top-tier content to its readership—researchers, medical professionals, and students—in order to advance knowledge and foster innovation in hepatology. With a broad and inclusive scope, it aims to cover significant breakthroughs, therapeutic advancements, and epidemiological studies, continually pushing the boundaries of understanding in liver health. The journal is based in Amsterdam, Netherlands, and remains an essential resource for those dedicated to the progression of hepatologic science.

SEMINARS IN LIVER DISEASE is a premier journal dedicated to advancing the field of hepatology, published by THIEME MEDICAL PUBL INC. Established in 1981, it has become a respected resource within the academic community, providing high-quality peer-reviewed articles that cover a broad range of topics related to liver diseases. With an impressive impact factor and recognized as a Q1 journal in the hepatology category, it ranks 17th out of 82 journals in the field, placing it in the top 21% of its category according to Scopus rankings. Although it does not offer open access, the journal’s rigorous standards and extensive network ensure that it reaches a wide audience of clinicians, researchers, and students, fostering knowledge and innovation in liver disease management. The journal's objectives focus on disseminating critical insights and promoting informed discussions that can pave the way for future research and clinical advancements in hepatology.

DIGESTIVE AND LIVER DISEASE is a prominent journal published by Elsevier Science Inc, dedicated to advancing the field of gastroenterology and hepatology. With an ISSN of 1590-8658 and an E-ISSN of 1878-3562, this journal has established itself as a significant resource within the academic community, especially considering its Q2 ranking in both gastroenterology and hepatology categories as of 2023. Spanning from 2000 to 2024, the journal presents a diverse array of peer-reviewed articles, clinical studies, and review papers that explore the latest advancements and research findings in digestive and liver diseases. The journal's robust impact, reflected in its Scopus rankings—40th out of 167 in gastroenterology and 28th out of 82 in hepatology—highlights its critical role in shaping practices and understanding in these vital areas of medicine. With open access options available, DIGESTIVE AND LIVER DISEASE aims to make high-quality research accessible to a wider audience, thereby encouraging collaboration and innovation. Researchers, healthcare professionals, and students alike will find valuable insights into the complex mechanisms, diagnostics, and therapeutic strategies pertinent to digestive and liver health.

Clinical Gastroenterology and Hepatology, published by Elsevier Science Inc, stands as a leading journal in the fields of gastroenterology and hepatology. With an ISSN of 1542-3565 and an E-ISSN of 1542-7714, this esteemed publication has earned its place in the top quartile (Q1) of both gastroenterology and hepatology categories as of 2023, ranking 6th out of 167 and 7th out of 82 respectively. The journal aims to disseminate innovative research, clinical studies, and case reports that advance the understanding and treatment of gastrointestinal and liver diseases. Targeted towards researchers, healthcare professionals, and students, it provides crucial insights into emerging therapies and medical advancements. Clinical Gastroenterology and Hepatology is not only a pivotal resource for contemporary gastroenterological research but also fosters collaboration and knowledge-sharing within the medical community. With a converging publication history from 2003 to the present, the journal continues to build on its solid foundation of scientific excellence and relevance.

Clinics in Liver Disease is an esteemed peer-reviewed journal published by W B Saunders Co-Elsevier Inc, dedicated to advancing the field of hepatology. Established in 1997 and covering a broad range of topics within liver disease research, this journal serves as a vital resource for researchers, clinicians, and students engaged in the study of liver health and diseases. With a commendable impact factor placing it within the Q2 category in Hepatology and ranking #32 out of 82 in the Scopus classifications, it consistently disseminates high-quality research and clinical insights. The journal’s commitment to promoting understanding and management of liver diseases is reflected in its rigorous editorial standards and comprehensive review processes. Although not an open-access publication, Clinics in Liver Disease offers subscription options that ensure accessibility to up-to-date research and reviews critical for both academic and clinical success.

REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, a pivotal Open Access journal published by ARAN EDICIONES, S A, has been at the forefront of advancing the field of gastroenterology since its inception in 1990. With a robust commitment to disseminating high-quality research, the journal provides a platform for researchers, clinicians, and students to share innovative findings and insights concerning digestive diseases. The journal is characterized by its Q3 ranking in both Gastroenterology and Miscellaneous Medicine categories, indicative of its significant contributions to these fields, and is positioned within the 36th percentile of Scopus rankings for medicine related to gastroenterology. Based in Spain, REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS has embraced the Open Access model since 2004, ensuring that its articles are readily available to a global audience without financial barriers. The journal not only supports academic discourse but also plays a crucial role in improving clinical practices and health outcomes related to digestive health.

Translational Gastroenterology and Hepatology, published by AME Publishing Company, stands as a pivotal platform for advancing the understanding and treatment of gastrointestinal and liver diseases. With its focus on translational research, this journal aims to bridge the gap between laboratory discoveries and clinical applications, thus fostering improvements in patient care. Although specific metrics like H-Index and Scopus ranks are currently unavailable, the journal is committed to maintaining high standards of scholarly communication and excellence. As an open-access publication, it ensures that valuable findings are readily accessible to a global audience, promoting collaboration and innovation among researchers, clinicians, and healthcare professionals invested in gastroenterology and hepatology. The journal's dedication to disseminating groundbreaking research makes it an essential resource for those seeking to stay at the forefront of these ever-evolving fields.

The International Journal of Hepatology, published by HINDAWI LTD, is a premier open-access journal dedicated to the field of hepatology. Since its inception, this journal has championed the dissemination of cutting-edge research and reviews pertaining to liver health, diseases, and therapies. With an ISSN of 2090-3448, the journal has been committed to open-access publishing since 2011, ensuring that vital knowledge is readily available to researchers, clinicians, and students worldwide. Based in Egypt, this journal stands out in its category, achieving a Q3 ranking in 2023 within the scope of Hepatology by Scopus, which ranks it #43 out of 82 in the field. The International Journal of Hepatology offers a platform for significant findings and discussions that influence clinical practices and foster new research directions, thus playing a crucial role in advancing the understanding of liver diseases and their management.

Hepatology Forum is an esteemed journal dedicated to disseminating cutting-edge research and insights in the fields of gastroenterology and hepatology. Published by KARE PUBL in Turkey, this journal serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to advance their knowledge and practices related to liver diseases and gastrointestinal disorders. With an ISSN of 1307-5888 and an E-ISSN of 2757-7392, it features peer-reviewed articles that encompass a wide range of topics from basic research to clinical applications. Although categorized in the Q3 quartile for both gastroenterology and hepatology in 2023, Hepatology Forum continues to show significant potential for growth and impact, as evidenced by its Scopus rankings. Through its commitment to open scientific exchange, the journal not only facilitates the sharing of innovative methodologies and findings but also fosters networking among professionals in the field. As it converges through the years from 2020 to 2024, Hepatology Forum remains an important resource for the advancement of liver health and diseases, appealing to both established experts and emerging scholars alike.